• Goldman Sachs sets a price target of $16 for NASDAQ:URGN, indicating a potential increase of about 33%.
• A class action lawsuit alleges securities fraud related to UroGen's ENVISION clinical study, impacting the stock's performance.
• Despite legal hurdles, URGN's stock price has seen a 12.01% increase, with a current trading price of $13.48.

UroGen Pharma Ltd. (NASDAQ:URGN) is a biopharmaceutical company focused on developing innovative therapies for urological diseases. The company is known for its lead pipeline product, UGN-102, which is designed to treat low-grade upper tract urothelial cancer. UroGen competes with other pharmaceutical companies in the urology space, striving to bring effective treatments to market.

On June 13, 2025, Paul Choi from Goldman Sachs set a price target of $16 for URGN, as reported by TheFly. At that time, the stock was priced at $12.03, suggesting a potential increase of about 33%. This optimistic outlook reflects confidence in UroGen's future performance, despite recent challenges.

A class action lawsuit has been filed against UroGen, alleging securities fraud related to the ENVISION clinical study. The lawsuit claims the study lacked a concurrent control, which is crucial for proving the effectiveness of UGN-102. This legal issue covers the period from July 27, 2023, to May 15, 2025, and shareholders are encouraged to join the lawsuit by July 28, 2025.

Currently, URGN is trading at $13.48, marking a 12.01% increase with a $1.45 price change. The stock has fluctuated between $12.61 and $14.42 today. Over the past year, it has seen a high of $19.01 and a low of $3.42. UroGen's market capitalization is approximately $621.3 million, with a trading volume of 4.9 million shares.

Despite the legal challenges, the recent price increase and Goldman Sachs' positive outlook suggest investor confidence in UroGen's potential. The company's ability to navigate these issues and deliver on its pipeline promises will be crucial for its future success.